RESUMEN
The Cannabis sativa plant contains more than 120 cannabinoids. With the exceptions of ∆9-tetrahydrocannabinol (∆9-THC) and cannabidiol (CBD), comparatively little is known about the pharmacology of the less-abundant plant-derived (phyto) cannabinoids. The best-studied transducers of cannabinoid-dependent effects are type 1 and type 2 cannabinoid receptors (CB1R, CB2R). Partial agonism of CB1R by ∆9-THC is known to bring about the 'high' associated with Cannabis use, as well as the pain-, appetite-, and anxiety-modulating effects that are potentially therapeutic. CB2R activation by certain cannabinoids has been associated with anti-inflammatory activities. We assessed the activity of 8 phytocannabinoids at human CB1R, and CB2R in Chinese hamster ovary (CHO) cells stably expressing these receptors and in C57BL/6 mice in an attempt to better understand their pharmacodynamics. Specifically, ∆9-THC, ∆9-tetrahydrocannabinolic acid (∆9-THCa), ∆9-tetrahydrocannabivarin (THCV), CBD, cannabidiolic acid (CBDa), cannabidivarin (CBDV), cannabigerol (CBG), and cannabichromene (CBC) were evaluated. Compounds were assessed for their affinity to receptors, ability to inhibit cAMP accumulation, ßarrestin2 recruitment, receptor selectivity, and ligand bias in cell culture; and cataleptic, hypothermic, anti-nociceptive, hypolocomotive, and anxiolytic effects in mice. Our data reveal partial agonist activity for many phytocannabinoids tested at CB1R and/or CB2R, as well as in vivo responses often associated with activation of CB1R. These data build on the growing body of literature showing cannabinoid receptor-dependent pharmacology for these less-abundant phytocannabinoids and are critical in understanding the complex and interactive pharmacology of Cannabis-derived molecules.
Asunto(s)
Analgésicos/farmacología , Ansiolíticos/farmacología , Agonistas de Receptores de Cannabinoides/farmacología , Cannabis/química , Psicotrópicos/farmacología , Receptor Cannabinoide CB1/genética , Receptor Cannabinoide CB2/genética , Analgésicos/aislamiento & purificación , Animales , Ansiolíticos/aislamiento & purificación , Células CHO , Cannabidiol/aislamiento & purificación , Cannabidiol/farmacología , Agonistas de Receptores de Cannabinoides/aislamiento & purificación , Cannabinoides/aislamiento & purificación , Cannabinoides/farmacología , Cricetulus , Dronabinol/análogos & derivados , Dronabinol/aislamiento & purificación , Dronabinol/farmacología , Expresión Génica , Humanos , Ratones Endogámicos C57BL , Extractos Vegetales/química , Psicotrópicos/aislamiento & purificación , Receptor Cannabinoide CB1/agonistas , Receptor Cannabinoide CB1/metabolismo , Receptor Cannabinoide CB2/agonistas , Receptor Cannabinoide CB2/metabolismo , Transgenes , Arrestina beta 2/genética , Arrestina beta 2/metabolismoRESUMEN
Cannabis is the most used illicit drug worldwide and its medicinal use is under discussion, being regulated in several countries. However, the psychotropic effects of Δ9-tetrahydrocannabinol (THC), the main psychoactive compound of Cannabis sativa, are of concern. Thus, the interest in the isolated constituents without psychotropic activity, such as cannabidiol (CBD) and cannabidivarin (CBDV) is growing. CBD and CBDV are lipophilic molecules with poor oral bioavailability and are mainly metabolized by cytochrome P450 (CYP450) enzymes. The pharmacodynamics of CBD is the best explored, being able to interact with diverse molecular targets, like cannabinoid receptors, G protein-coupled receptor-55, transient receptor potential vanilloid 1 channel and peroxisome proliferator-activated receptor-γ. Considering the therapeutic potential, several clinical trials are underway to study the efficacy of CBD and CBDV in different pathologies, such as neurodegenerative diseases, epilepsy, autism spectrum disorders and pain conditions. The anti-cancer properties of CBD have also been demonstrated by several pre-clinical studies in different types of tumour cells. Although less studied, CBDV, a structural analogue of CBD, is receiving attention in the last years. CBDV exhibits anticonvulsant properties and, currently, clinical trials are underway for the treatment of autism spectrum disorders. Despite the benefits of these phytocannabinoids, it is important to highlight their potential interference with relevant physiologic mechanisms. In fact, CBD interactions with CYP450 enzymes and with drug efflux transporters may have serious consequences when co-administered with other drugs. This review summarizes the therapeutic advances of CBD and CBDV and explores some aspects of their pharmacokinetics, pharmacodynamics and possible interactions. Moreover, it also highlights the therapeutic potential of CBD and CBDV in several medical conditions and clinical applications.
Asunto(s)
Antiinflamatorios/uso terapéutico , Anticonvulsivantes/uso terapéutico , Antineoplásicos Fitogénicos/uso terapéutico , Cannabinoides/uso terapéutico , Cannabis/química , Dronabinol/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Animales , Antiinflamatorios/aislamiento & purificación , Antiinflamatorios/farmacocinética , Anticonvulsivantes/aislamiento & purificación , Anticonvulsivantes/farmacocinética , Antineoplásicos Fitogénicos/aislamiento & purificación , Antineoplásicos Fitogénicos/farmacocinética , Cannabinoides/aislamiento & purificación , Cannabinoides/farmacocinética , Dronabinol/aislamiento & purificación , Dronabinol/farmacocinética , Interacciones Farmacológicas , Humanos , Fármacos Neuroprotectores/aislamiento & purificación , Fármacos Neuroprotectores/farmacocinéticaRESUMEN
Cannabis (marijuana) is one of the most consumed psychoactive substances in the world. The term marijuana is of Mexican origin. The primary cannabinoids that have been studied to date include cannabidiol and delta-9-tetrahydrocannabinol, which is responsible for most cannabis physical and psychotropic effects. Recently, the endocannabinoid system was discovered, which is made up of receptors, ligands and enzymes that are widely expressed in the brain and its periphery, where they act to maintain balance in several homeostatic processes. Exogenous cannabinoids or naturally-occurring phytocannabinoids interact with the endocannabinoid system. Marijuana must be processed in a laboratory to extract tetrahydrocannabinol and leave cannabidiol, which is the product that can be marketed. Some studies suggest cannabidiol has great potential for therapeutic use as an agent with antiepileptic, analgesic, anxiolytic, antipsychotic, anti-inflammatory and neuroprotective properties; however, the findings on cannabinoids efficacy and cannabis-based medications tolerability-safety for some conditions are inconsistent. More scientific evidence is required in order to generate recommendations on the use of medicinal cannabis.
El cannabis (marihuana) es una de las sustancias psicoactivas más consumidas en el mundo. El término marihuana es de origen mexicano. Los cannabinoides primarios estudiados hasta la fecha incluyen el cannabidiol y el delta-9-tetrahidrocannabinol (Δ9-THC), responsable de la mayoría de los efectos físicos y psicotrópicos del cannabis. Recientemente se descubrió el sistema endocannabinoide formado por receptores, ligandos y enzimas expresados ampliamente en el cerebro y su periferia, donde actúan para mantener el equilibrio en varios procesos homeostáticos. Los cannabinoides exógenos o fitocannabinoides de origen natural interactúan con el sistema endocannabinoide. La marihuana debe ser procesada en un laboratorio para extraer el tetrahidrocannabinol y dejar el cannabidiol, el producto que se puede comercializar. Algunos estudios otorgan al cannabidiol un gran potencial para el uso terapéutico como antiepiléptico, analgésico, ansiolítico, antipsicótico, antiinflamatorio y neuroprotector, sin embargo, son inconsistentes los hallazgos sobre la eficacia de los cannabinoides y la tolerabilidad-seguridad de los medicamentos con base en cannabis para cualquier padecimiento. Se requiere más evidencia científica para generar recomendaciones sobre el uso del cannabis medicinal.
Asunto(s)
Cannabidiol/uso terapéutico , Endocannabinoides/metabolismo , Marihuana Medicinal/uso terapéutico , Animales , Encéfalo/metabolismo , Cannabidiol/aislamiento & purificación , Cannabidiol/metabolismo , Cannabis/química , Dronabinol/aislamiento & purificación , Dronabinol/metabolismo , Dronabinol/farmacología , Humanos , Ratas , Receptor Cannabinoide CB1/metabolismo , Receptor Cannabinoide CB2/metabolismo , Receptores de Cannabinoides/metabolismo , Porcinos , Canales Catiónicos TRPV/metabolismoRESUMEN
The aim of this work was to optimize a maceration condition of cannabis (Cannabis sativa L.). A circumscribed central composite experimental design was applied in this work. Temperature and time were varied from 40-80 °C and 30-90 min, respectively. The three responses (i.e., extraction yield, cannabidiol content, and Δ9- tetrahydrocannabinol content) were predicted by computer software. The yield was high when cannabis was macerated using ethanol at high temperature and long duration time. While cannabidiol and Δ9- tetrahydrocannabinol content was high when macerating at a low heating temperature and short duration time. The optimal condition provided the simultaneous high of cannabidiol and Δ9- tetrahydrocannabinol content was 40 °C for 30 min. The prediction was accurate due to low percent error. This optimal condition could be used as a guide for maceration of cannabis to obtain the extract containing a high content of cannabidiol and Δ9- tetrahydrocannabinol.
Asunto(s)
Cannabidiol/análisis , Cannabis/química , Dronabinol/aislamiento & purificación , Extractos Vegetales/análisis , Cromatografía Líquida de Alta Presión , Dronabinol/análisis , Métodos , Temperatura , Factores de TiempoRESUMEN
Cannabis (marijuana) is one of the most consumed psychoactive substances in the world. The term marijuana is of Mexican origin. The primary cannabinoids that have been studied to date include cannabidiol and delta-9-tetrahydrocannabinol, which is responsible for most cannabis physical and psychotropic effects. Recently, the endocannabinoid system was discovered, which is made up of receptors, ligands and enzymes that are widely expressed in the brain and its periphery, where they act to maintain balance in several homeostatic processes. Exogenous cannabinoids or naturally-occurring phytocannabinoids interact with the endocannabinoid system. Marijuana must be processed in a laboratory to extract tetrahydrocannabinol and leave cannabidiol, which is the product that can be marketed. Some studies suggest cannabidiol has great potential for therapeutic use as an agent with antiepileptic, analgesic, anxiolytic, antipsychotic, anti-inflammatory and neuroprotective properties; however, the findings on cannabinoids efficacy and cannabis-based medications tolerability-safety for some conditions are inconsistent. More scientific evidence is required in order to generate recommendations on the use of medicinal cannabis.
Asunto(s)
Humanos , Animales , Conejos , Cannabidiol/uso terapéutico , Endocannabinoides/metabolismo , Marihuana Medicinal/uso terapéutico , Porcinos , Dronabinol/aislamiento & purificación , Dronabinol/farmacología , Cannabidiol/aislamiento & purificación , Cannabinoides/farmacología , Cannabis , Receptor Cannabinoide CB1/metabolismo , Receptor Cannabinoide CB2/metabolismo , Canales Catiónicos TRPV/metabolismoRESUMEN
BACKGROUND AND PURPOSE: Duchenne muscular dystrophy (DMD), caused by dystrophin deficiency, results in chronic inflammation and irreversible skeletal muscle degeneration. Moreover, the associated impairment of autophagy greatly contributes to the aggravation of muscle damage. We explored the possibility of using non-euphoric compounds present in Cannabis sativa, cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabidivarin (THCV), to reduce inflammation, restore functional autophagy and positively enhance muscle function in vivo. EXPERIMENTAL APPROACH: Using quantitative PCR, western blots and [Ca2+ ]i measurements, we explored the effects of CBD and CBDV on the differentiation of both murine and human skeletal muscle cells as well as their potential interaction with TRP channels. Male dystrophic mdx mice were injected i.p. with CBD or CBDV at different stages of the disease. After treatment, locomotor tests and biochemical analyses were used to evaluate their effects on inflammation and autophagy. KEY RESULTS: CBD and CBDV promoted the differentiation of murine C2C12 myoblast cells into myotubes by increasing [Ca2+ ]i mostly via TRPV1 activation, an effect that undergoes rapid desensitization. In primary satellite cells and myoblasts isolated from healthy and/or DMD donors, not only CBD and CBDV but also THCV promoted myotube formation, in this case, mostly via TRPA1 activation. In mdx mice, CBD (60 mg·kg-1 ) and CBDV (60 mg·kg-1 ) prevented the loss of locomotor activity, reduced inflammation and restored autophagy. CONCLUSION AND IMPLICATIONS: We provide new insights into plant cannabinoid interactions with TRP channels in skeletal muscle, highlighting a potential opportunity for novel co-adjuvant therapies to prevent muscle degeneration in DMD patients. LINKED ARTICLES: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.
Asunto(s)
Cannabidiol/farmacología , Cannabinoides/farmacología , Cannabis/química , Dronabinol/análogos & derivados , Músculo Esquelético/efectos de los fármacos , Distrofia Muscular de Duchenne/tratamiento farmacológico , Mioblastos/efectos de los fármacos , Animales , Calcio/metabolismo , Cannabidiol/aislamiento & purificación , Cannabinoides/aislamiento & purificación , Diferenciación Celular/efectos de los fármacos , Línea Celular , Relación Dosis-Respuesta a Droga , Dronabinol/aislamiento & purificación , Dronabinol/farmacología , Distrofina/genética , Endocannabinoides/metabolismo , Humanos , Masculino , Ratones , Fuerza Muscular/efectos de los fármacos , Fuerza Muscular/genética , Músculo Esquelético/metabolismo , Distrofia Muscular de Duchenne/metabolismo , Mioblastos/metabolismo , Canales de Potencial de Receptor Transitorio/metabolismoRESUMEN
Cannabis (marijuana) is one of the most consumed psychoactive substances in the world. The term marijuana is of Mexican origin. The primary cannabinoids that have been studied to date include cannabidiol and delta-9-tetrahydrocannabinol, which is responsible for most cannabis physical and psychotropic effects. Recently, the endocannabinoid system was discovered, which is made up of receptors, ligands and enzymes that are widely expressed in the brain and its periphery, where they act to maintain balance in several homeostatic processes. Exogenous cannabinoids or naturally-occurring phytocannabinoids interact with the endocannabinoid system. Marijuana must be processed in a laboratory to extract tetrahydrocannabinol and leave cannabidiol, which is the product that can be marketed. Some studies suggest cannabidiol has great potential for therapeutic use as an agent with antiepileptic, analgesic, anxiolytic, antipsychotic, anti-inflammatory and neuroprotective properties; however, the findings on cannabinoids efficacy and cannabis-based medications tolerability-safety for some conditions are inconsistent. More scientific evidence is required in order to generate recommendations on the use of medicinal cannabis.
Asunto(s)
Cannabidiol/uso terapéutico , Endocannabinoides/metabolismo , Marihuana Medicinal/uso terapéutico , Animales , Cannabidiol/aislamiento & purificación , Cannabinoides/farmacología , Cannabis , Dronabinol/aislamiento & purificación , Dronabinol/farmacología , Humanos , Ratones , Receptor Cannabinoide CB1/metabolismo , Receptor Cannabinoide CB2/metabolismo , Porcinos , Canales Catiónicos TRPV/metabolismoRESUMEN
The therapeutic application of cannabis is attracting substantial public and clinical interest. The cannabis plant has been described as a veritable 'treasure trove', producing more than 100 different cannabinoids, although the focus to date has been on the psychoactive molecule delta-9-tetraydrocannabinol (THC) and cannabidiol (CBD). Other numerous secondary metabolites of cannabis, the terpenes, some of which share the common intermediary geranyl diphosphate (GPP) with the cannabinoids, are hypothesized to contribute synergistically to their therapeutic benefits, an attribute that has been described as the 'entourage effect'. The effective delivery of such a complex multicomponent pharmaceutical relies upon the stable genetic background and standardized growth of the plant material, particularly if the raw botanical product in the form of the dried pistillate inflorescence (flos) is the source. Following supercritical CO2 extraction of the inflorescence (and possibly bracts), the secondary metabolites can be blended to provide a specific ratio of major cannabinoids (THC : CBD) or individual cannabinoids can be isolated, purified and supplied as the pharmaceutical. Intensive breeding strategies will provide novel cultivars of cannabis possessing elevated levels of specific cannabinoids or other secondary metabolites.
Asunto(s)
Cannabinoides/aislamiento & purificación , Cannabis/química , Extractos Vegetales/química , Cannabidiol/aislamiento & purificación , Cannabidiol/farmacología , Cannabinoides/química , Cannabinoides/farmacología , Cannabis/metabolismo , Dronabinol/aislamiento & purificación , Dronabinol/farmacología , Humanos , Extractos Vegetales/farmacología , Metabolismo Secundario , Terpenos/aislamiento & purificación , Terpenos/farmacologíaAsunto(s)
Cannabidiol/uso terapéutico , Cannabinoides/uso terapéutico , Cannabis , Dronabinol/análogos & derivados , Marihuana Medicinal/uso terapéutico , Extractos Vegetales/uso terapéutico , Administración Oral , Analgésicos/uso terapéutico , Anticonvulsivantes/uso terapéutico , Antieméticos/uso terapéutico , Cannabidiol/administración & dosificación , Cannabidiol/efectos adversos , Cannabidiol/aislamiento & purificación , Cannabinoides/administración & dosificación , Cannabinoides/efectos adversos , Cannabinoides/aislamiento & purificación , Cannabis/química , Dronabinol/administración & dosificación , Dronabinol/efectos adversos , Dronabinol/aislamiento & purificación , Dronabinol/uso terapéutico , Combinación de Medicamentos , Interacciones Farmacológicas , Humanos , Marihuana Medicinal/administración & dosificación , Marihuana Medicinal/efectos adversos , Parasimpatolíticos/uso terapéutico , Extractos Vegetales/administración & dosificación , Extractos Vegetales/efectos adversos , Extractos Vegetales/aislamiento & purificaciónRESUMEN
In The Netherlands, pharmaceutical-grade cultivated cannabis is distributed for medicinal purposes as commissioned by the Ministry of Health. Few studies have thus far described its therapeutic efficacy or subjective (adverse) effects in patients. The aims of this study are to assess the therapeutic satisfaction within a group of patients using prescribed pharmaceutical-grade cannabis and to compare the subjective effects among the available strains with special focus on their delta-9-tetrahydrocannabinol and cannabidiol content. In a cross-sectional and natural design, users of pharmaceutical-grade cannabis were investigated with questionnaires. Medical background of the patients was asked as well as experienced therapeutic effects and characteristics of cannabis use. Subjective effects were measured with psychometric scales and used to compare among the strains of cannabis used across this group of patients. One hundred two patients were included; their average age was 53 years and 76% used it for more than a year preceding this study. Chronic pain (53%; n = 54) was the most common medical indication for using cannabis followed by multiple sclerosis (23%; n = 23), and 86% (n = 88) of patients (almost) always experienced therapeutic satisfaction when using pharmaceutical cannabis. Dejection, anxiety, and appetite stimulation were found to differ among the 3 strains of cannabis. These results show that patients report therapeutic satisfaction with pharmaceutical cannabis, mainly pain alleviation. Some subjective effects were found to differ among the available strains of cannabis, which is discussed in relation to their different tetrahydrocannabinol/cannabidiol content. These results may aid in further research and critical appraisal for medicinally prescribed cannabis products.
Asunto(s)
Cannabis/química , Dolor Crónico/tratamiento farmacológico , Fitoterapia/métodos , Preparaciones de Plantas/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Cannabidiol/aislamiento & purificación , Estudios Transversales , Dronabinol/aislamiento & purificación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/tratamiento farmacológico , Países Bajos , Satisfacción del Paciente , Fitoterapia/efectos adversos , Preparaciones de Plantas/efectos adversos , Preparaciones de Plantas/química , Psicometría , Encuestas y Cuestionarios , Resultado del Tratamiento , Adulto JovenRESUMEN
Cannabis is the most widely used illicit substance globally, with an estimated annual prevalence in 2010 of 2.6-5.0% of the adult population. Concerns have been expressed about increases in the potency of cannabis products. A high tetrahydrocannabinol (THC) content can increase anxiety, depression, and psychotic symptoms, and can increase the risk of dependence and adverse effects on the respiratory and cardiovascular systems in regular users. The aim of this study was to report statistical data about the potency of cannabis products seized in the north-east of Italy, in a geographical area centred in Venice and extending for more than 10,000 km(2) with a population of more than two million, by investigating the variability observed in THC levels of about 4000 samples of cannabis products analyzed over the period 2010-2012. Overall median THC content showed an increasing trend over the study period from about 6.0% to 8.1% (6.2-8.9% for cannabis resin, 5.1-7.6% for herbal cannabis). The variation in the THC content of individual samples was very large, ranging from 0.3% to 31% for cannabis resin and from 0.1 to 19% for herbal cannabis. Median CBN:THC ratios showed a slightly decreasing trend over the study period, from 0.09 (2010) to 0.03 (2012), suggesting an increasing freshness of submitted materials. Median CBD:THC ratios also showed a decreasing trend over the study from about 0.52 (2010) to 0.18 (2012), likely due to the increase in submissions of materials from indoor and domestic cultivation with improved breeding methods.
Asunto(s)
Cannabinoides/química , Cannabis/química , Extractos Vegetales/química , Cannabinoides/aislamiento & purificación , Dronabinol/química , Dronabinol/aislamiento & purificación , Italia , Extractos Vegetales/aislamiento & purificaciónRESUMEN
A cloud point extraction coupled with high performance liquid chromatography (HPLC/UV) method was developed for the determination of Δ(9)-tetrahydrocannabinol (THC) in micellar phase. The nonionic surfactant "Dowfax 20B102" was used to extract and pre-concentrate THC from cannabis resin, prior to its determination with a HPLC-UV system (diode array detector) with isocratic elution. The parameters and variables affecting the extraction were investigated. Under optimum conditions (1 wt.% Dowfax 20B102, 1 wt.% Na2SO4, T = 318 K, t = 30 min), this method yielded a quite satisfactory recovery rate (~81 %). The limit of detection was 0.04 µg mL(-1), and the relative standard deviation was less than 2 %. Compared with conventional solid-liquid extraction, this new method avoids the use of volatile organic solvents, therefore is environmentally safer.
Asunto(s)
Cannabis/química , Fraccionamiento Químico/métodos , Cromatografía Líquida de Alta Presión/métodos , Dronabinol/aislamiento & purificación , Extractos Vegetales/aislamiento & purificación , Resinas de Plantas/química , Dronabinol/análisis , Extractos Vegetales/análisisRESUMEN
Two isolation procedures for Δ9-tetrahydrocannabinolic acid A (THCA), the biogenetic precursor in the biosynthesis of the psychoactive Δ9-tetrahydrocannabinol (THC) in the cannabis plant, are presented. Two flash chromatography systems that can be used independently from each other were developed to separate THCA from other compounds of a crude cannabis extract. In both systems UV absorption at 209 and 270 nm was monitored. Purity was finally determined by HPLC-DAD, NMR and GC-MS analysis with a focus on the impurity THC. System 1 consisted of a normal phase silica column (120 g) as well as cyclohexane and acetone--both spiked with the modifier pyridine--as mobile phases. Gradient elution was performed over 15 min. After the chromatographic run the fractions containing THCA fractions were pooled, extracted with hydrochloric acid to eliminate pyridine and evaporated to dryness. Loading 1800 mg cannabis extract yielded 623 mg THCA with a purity of 99.8% and a THC concentration of 0.09%. System 2 was based on a reversed-phase C18 column (150 g) combined with 0.55% formic acid and methanol as mobile phases. A very flat gradient was set over 20 minutes. After pooling the THCA-containing fractions methanol was removed in a rotary evaporator. THCA was re-extracted from the remaining aqueous phase with methyl tert-butyl ether. The organic phase was finally evaporated under high vacuum conditions. Loading 300 mg cannabis extract yielded 51 mg THCA with a purity of 98.8% and a THC concentration of 0.67%.
Asunto(s)
Cannabis/química , Cromatografía Liquida/métodos , Dronabinol/análogos & derivados , Extractos Vegetales/aislamiento & purificación , Cromatografía Liquida/instrumentación , Dronabinol/análisis , Dronabinol/aislamiento & purificación , Extractos Vegetales/análisisRESUMEN
GC is commonly used for the analysis of cannabis samples, e.g. in forensic chemistry. However, as this method is based on heating of the sample, acidic forms of cannabinoids are decarboxylated into their neutral counterparts. Conversely, HPLC permits the determination of the original composition of plant cannabinoids by direct analysis. Several HPLC methods have been described in the literature, but most of them failed to separate efficiently all the cannabinoids or were not validated according to general guidelines. By use of an innovative methodology for modelling chromatographic responses, a simple and accurate HPLC/DAD method was developed for the quantification of major neutral and acidic cannabinoids present in cannabis plant material: Delta9-tetrahydrocannabinol (THC), THC acid (THCA), cannabidiol (CBD), CBD acid (CBDA), cannabigerol (CBG), CBG acid (CBGA) and cannabinol (CBN). Delta8-Tetrahydrocannabinol (Delta8-THC) was determined qualitatively. Following the practice of design of experiments, predictive multilinear models were developed and used in order to find optimal chromatographic analytical conditions. The method was validated following an approach using accuracy profiles based on beta-expectation tolerance intervals for the total error measurement, and assessing the measurements uncertainty. This analytical method can be used for diverse applications, e.g. plant phenotype determination, evaluation of psychoactive potency and control of material quality.
Asunto(s)
Cannabinoides/análisis , Cannabis/química , Cromatografía Líquida de Alta Presión/métodos , Extractos Vegetales/análisis , Cannabidiol/análisis , Cannabidiol/aislamiento & purificación , Cannabinoides/aislamiento & purificación , Dronabinol/análisis , Dronabinol/aislamiento & purificación , Estructura Molecular , Extractos Vegetales/aislamiento & purificación , Sensibilidad y EspecificidadRESUMEN
Type 2 diabetes, a chronic disease, affects about 150 million people world wide. It is characterized by insulin resistance of peripheral tissues such as liver, skeletal muscle, and fat. Insulin resistance is associated with elevated levels of tumor necrosis factor alpha (TNF-alpha), which in turn inhibits insulin receptor tyrosine kinase autophosphorylation. It has been reported that cannabis is used in the treatment of diabetes. A few reports indicate that smoking cannabis can lower blood glucose in diabetics. Delta(9)-tetrahydrocannabinol (THC) is the primary psychoactive component of cannabis. This study aimed to determine the effect of a lipophilic cannabis extract on adipogenesis, using 3T3-L1 cells, and to measure its effect on insulin sensitivity in insulin resistant adipocytes. Cells were cultured in Dulbecco's modified eagle medium (DMEM) with 10% fetal bovine serum (FBS) and differentiated over a 3 day period for all studies. In the adipogenesis studies, differentiated cells were exposed to the extract in the presence and absence of insulin. Lipid content and glucose uptake was subsequently measured. Insulin-induced glucose uptake increased, while the rate of adipogenesis decreased with increasing THC concentration. Insulin-resistance was induced using TNF-alpha, exposed to the extract and insulin-induced glucose uptake measured. Insulin-induced glucose was increased in these cells after exposure to the extract. Semiquantitative real time polymerase chain reaction (RT-PCR) was performed after ribonucleic acid (RNA) extraction to evaluate the effects of the extract on glucose transporter isotype 4 (GLUT-4), insulin receptor substrate-1 (IRS-1) and IRS-2 gene expression.
Asunto(s)
Adipocitos/efectos de los fármacos , Adipogénesis/efectos de los fármacos , Cannabis/química , Dronabinol/farmacología , Resistencia a la Insulina , Células 3T3-L1 , Adipocitos/metabolismo , Animales , Dronabinol/aislamiento & purificación , Glucosa/metabolismo , Insulina/metabolismo , Ratones , Extractos Vegetales/farmacología , Triglicéridos/biosíntesisRESUMEN
Cannabis sativa L. is the source for a whole series of chemically diverse bioactive compounds that are currently under intensive pharmaceutical investigation. In this work, hot and cold water extracts as well as ethanol/water mixtures (tinctures) of cannabis were compared in order to better understand how these extracts differ in their overall composition. NMR analysis and in vitro cell assays of crude extracts and fractions were performed. Manufacturing procedures to produce natural remedies can strongly affect the final composition of the herbal medicines. Temperature and polarity of the solvents used for the extraction resulted to be two factors that affect the total amount of Delta(9)-THC in the extracts and its relative quantity with respect to Delta(9)-THC-acid and other metabolites. Diffusion-edited (1)H NMR (1D DOSY) and (1)H NMR with suppression of the ethanol and water signals were used. With this method it was possible, without any evaporation or separation step, to distinguish between tinctures from different cannabis cultivars. This approach is proposed as a direct analysis of plant tinctures.
Asunto(s)
Ácidos/química , Cannabis/química , Dronabinol/química , Dronabinol/aislamiento & purificación , Agua/química , Espectroscopía de Resonancia Magnética , Estructura Molecular , Extractos Vegetales/química , Solventes/químicaRESUMEN
OBJECTIVE: To select the optimum extracting procedure for cannabinoids from hemp seed oil. METHODS: The optimum extracting procedure was selected with the content of cannabinol and delta9-tetrehydrocannabinol from hemp seed oil by orthogonal test design. We have examined three factors that may influence the extraction rate: the time of extraction, the times of extraction and the amount of methanol. RESULTS: The optimum extraction condition was adding 5 ml, two times amount of methanol into hemp seed oil for 15 min. CONCLUSION: The above extraction process gave the most rational, stable, feasible and satisfactory results. The method is convenient.
Asunto(s)
Cannabinoides/aislamiento & purificación , Cannabis/química , Aceites de Plantas/química , Plantas Medicinales/química , Tecnología Farmacéutica/métodos , Cannabinoides/análisis , Cannabinoides/química , Cromatografía Líquida de Alta Presión , Dronabinol/análisis , Dronabinol/aislamiento & purificación , Metanol , Semillas/química , Factores de Tiempo , UltrasonidoRESUMEN
Cannabinoid receptors in the brain (CB(1)) take part in modulation of learning, and are particularly important for working and short-term memory. Here, we employed a delayed-matching-to-place (DMTP) task in the open-field water maze and examined the effects of cannabis plant extracts rich in either Delta(9)-tetrahydrocannabinol (Delta(9)-THC), or rich in cannabidiol (CBD), on spatial working and short-term memory formation in rats. Delta(9)-THC-rich extracts impaired performance in the memory trial (trial 2) of the DMTP task in a dose-dependent but delay-independent manner. Deficits appeared at doses of 2 or 5 mg/kg (i.p.) at both 30 s and 4 h delays and were similar in severity compared with synthetic Delta(9)-THC. Despite considerable amounts of Delta(9)-THC present, CBD-rich extracts had no effect on spatial working/short-term memory, even at doses of up to 50 mg/kg. When given concomitantly, CBD-rich extracts did not reverse memory deficits of the additional Delta(9)-THC-rich extract. CBD-rich extracts also did not alter Delta(9)-THC-rich extract-induced catalepsy as revealed by the bar test. It appears that spatial working/short-term memory is not sensitive to CBD-rich extracts and that potentiation and antagonism of Delta(9)-THC-induced spatial memory deficits is dependent on the ratio between CBD and Delta(9)-THC.
Asunto(s)
Cannabidiol/farmacología , Dronabinol/farmacología , Memoria/efectos de los fármacos , Animales , Cannabidiol/aislamiento & purificación , Relación Dosis-Respuesta a Droga , Dronabinol/aislamiento & purificación , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Aprendizaje por Laberinto/fisiología , Memoria/fisiología , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , Ratas , Receptor Cannabinoide CB1/agonistas , Receptor Cannabinoide CB1/fisiologíaRESUMEN
Cannabinoids can modulate the function of immune cells. We here present the first human in vivo study measuring immune function in 16 MS patients treated with oral cannabinoids. A modest increase of TNF-alpha in LPS-stimulated whole blood was found during cannabis plant-extract treatment (p=0.037), with no change in other cytokines. In the subgroup of patients with high adverse event scores, we found an increase in plasma IL-12p40 (p=0.002). The results suggest pro-inflammatory disease-modifying potential of cannabinoids in MS.
Asunto(s)
Adyuvantes Inmunológicos/farmacología , Cannabinoides/farmacología , Dronabinol/uso terapéutico , Esclerosis Múltiple/tratamiento farmacológico , Esclerosis Múltiple/inmunología , Extractos Vegetales/farmacología , Adyuvantes Inmunológicos/efectos adversos , Adyuvantes Inmunológicos/aislamiento & purificación , Administración Oral , Adulto , Cannabinoides/efectos adversos , Cannabinoides/aislamiento & purificación , Cannabis , Intervalos de Confianza , Estudios Cruzados , Dronabinol/aislamiento & purificación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/sangre , Fitoterapia/métodos , Extractos Vegetales/efectos adversos , Extractos Vegetales/aislamiento & purificaciónRESUMEN
Cannabis is under clinical investigation to assess its potential for medicinal use, but the question arises as to whether there is any advantage in using cannabis extracts compared with isolated Delta9-trans-tetrahydrocannabinol (Delta9THC), the major psychoactive component. We have compared the effect of a standardized cannabis extract (SCE) with pure Delta9THC, at matched concentrations of Delta9THC, and also with a Delta9THC-free extract (Delta9THC-free SCE), using two cannabinoid-sensitive models, a mouse model of multiple sclerosis (MS), and an in-vitro rat brain slice model of epilepsy. Whilst SCE inhibited spasticity in the mouse model of MS to a comparable level, it caused a more rapid onset of muscle relaxation, and a reduction in the time to maximum effect compared with Delta9THC alone. The Delta9THC-free extract or cannabidiol (CBD) caused no inhibition of spasticity. However, in the in-vitro epilepsy model, in which sustained epileptiform seizures were induced by the muscarinic receptor agonist oxotremorine-M in immature rat piriform cortical brain slices, SCE was a more potent and again more rapidly-acting anticonvulsant than isolated Delta9THC, but in this model, the Delta9THC-free extract also exhibited anticonvulsant activity. Cannabidiol did not inhibit seizures, nor did it modulate the activity of Delta9THC in this model. Therefore, as far as some actions of cannabis were concerned (e.g. antispasticity), Delta9THC was the active constituent, which might be modified by the presence of other components. However, for other effects (e.g. anticonvulsant properties) Delta9THC, although active, might not be necessary for the observed effect. Above all, these results demonstrated that not all of the therapeutic actions of cannabis herb might be due to the Delta9THC content.